Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study

Table 2

Baseline demographic and clinical characteristics of two propensity-matched groups (n=207).

Characteristic	TACE+sorafenib; (n=69)	TACE; (n=168)	X^2/t/z; Value	P Value
Age	50.85±11.52	51.4±11.20	-0.357	0.722
Sex
Male	59	117	0.019	0.890
Female	10	21
Child-Pugh
A	67	133	0.074	0.786
B	2	5
AFP	12307.24±20255.88	13774.00±21995.32	-0.464	0.343
Number
<3	58	173	0.009	0.925
≥3	11	34
Size	8.39±4.45	8.55±3.39	-0.285	0.795
Type
I/II	43	88	0.042	0.838
III/IV	26	50
Treatment after TACE
surgery	1	2	0.085	0.958
RFA	1	3
radiotherapy	2	6

p<0.05